To read this content please select one of the options below:

Drivers of voluntary intellectual capital disclosure in listed biotechnology companies

Gregory White (School of Accounting, Curtin Business School, Curtin University of Technology, Perth, Australia)
Alina Lee (School of Accounting, Curtin Business School, Curtin University of Technology, Perth, Australia)
Greg Tower (School of Accounting, Curtin Business School, Curtin University of Technology, Perth, Australia)

Journal of Intellectual Capital

ISSN: 1469-1930

Article publication date: 31 July 2007

3327

Abstract

Purpose

The paper seeks to investigate the key drivers and level of voluntary disclosures in biotechnology company annual reports.

Design/methodology/approach

The paper uses an intellectual capital disclosure index score of voluntary disclosures in a large sample of listed biotechnology companies, and tests the relationship between voluntary disclosures of intangible firm value with traditional agency theory variables. The relationships are tested statistically using correlation and multiple‐regression analysis.

Findings

The key drivers of voluntary intellectual capital disclosures were the level of board independence, firm age, level of leverage and firm size. Multiple regression analysis demonstrated that board independence, leverage and size had a significant relationship with the level of voluntary intellectual capital disclosure. Separate regression controlling for large‐sized and small‐sized firms demonstrated that voluntary intellectual capital disclosure was only driven by board independence and the levels of firm leverage in large firms. Small firms did not demonstrate this relationship.

Research limitations/implications

The implications of this research are that smaller biotechnology companies' managers are not motivated by external debt‐holder demands to make voluntary disclosures about intangible firm value. In addition, large biotechnology companies, which are better able to establish independent board oversight, appear more effective at driving voluntary intellectual capital disclosures, perhaps in response to greater demand by owners. A limitation of this study is its Australian context and that data is analysed only from 2005 financial year annual reports.

Originality/value

To the authors' knowledge this is an original paper whose findings have valuable implications for managing intellectual capital at the firm level. The paper clearly demonstrates that disclosures about intangible firm value is being driven by traditional agency theory variables and more contemporary corporate governance issues, and that small firms may be ignoring the importance of disclosing more about their intellectual capital.

Keywords

Citation

White, G., Lee, A. and Tower, G. (2007), "Drivers of voluntary intellectual capital disclosure in listed biotechnology companies", Journal of Intellectual Capital, Vol. 8 No. 3, pp. 517-537. https://doi.org/10.1108/14691930710774894

Publisher

:

Emerald Group Publishing Limited

Copyright © 2007, Emerald Group Publishing Limited

Related articles